Loading…
SOLV
Solventum Corp
NYSE· Healthcare· Medical Instruments & Supplies· CUSIP 83444M101
$87.45+0.90%Price as of Oct 23, 00:48 UTC · updated once a day, after the close
At a glance
Solventum Corp (SOLV) is listed on NYSE and classified in Medical Instruments & Supplies, part of the Healthcare sector. It is headquartered in Eagan, United States and has 20,584 employees. The company is worth $14.89B and trades at 10.6x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $8.33B in fiscal 2025, up 0.9% from the year before. Net income was $1.56B. The share price is 7.1% below its 52-week high of $94.16. 6 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Israel Englander (Millennium Management), at $92.58M. In that quarter, 4 of them opened or added to the position and 1 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $14.89B
- P/E
- 10.6x
- Forward P/E
- 12.1x
- P/B
- 3.1x
- Dividend yield
- 0.00%
- Payout
- —
- EPS
- $8.24
- ROE
- 33.96%
- Profit margin
- 17.26%
- Revenue growth
- +2.20%
- Beta
- 0.70
- 52-week high
- $94.16
- 52-week low
- $62.38
History
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▲ +23.4% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 2 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 |
|---|---|---|---|
| Year-end price | $79.24 | $66.06 | |
| P/E | — | 8.9x | 23.9x |
| P/S | — | 1.7x | 1.4x |
| P/B | — | 2.7x | 3.9x |
| EPS | $8.88 | $2.76 | |
| Profit margin | — | 18.69% | 5.80% |
| ROE | — | 30.82% | 16.19% |
Fair price, seven ways
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Earnings
$72.33
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings
$37.14
Earnings growing 4.5% a year plus a 0.0% dividend yield. Growth capped at 25%.
Earnings
$200.11
Median P/E of 24.3 among peers in the sector.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Operating
$192.49
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
Dividends
—
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| NBIXNeurocrine Biosciences Inc | $143.29 | 20.7x | 3.9x | 0.00% | 22.09% | $14.57B |
| ICLRIcon PLC | $185.43 | 195.2x | 1.5x | 0.00% | 0.29% | $14.31B |
| HALOHalozyme Therapeutics Inc | $124.54 | 36.5x | 98.9x | 0.00% | 173.67% | $14.14B |
| JAZZJazz Pharmaceuticals plc |
About the company
- 20,584
- Eagan, United States
